| Name | Title | Contact Details |
|---|
SAIC-Frederick is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon`s aim is to build strong client partnerships with the world`s best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.
Victor International Mktg Inc is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sage Bionetworks is a nonprofit biomedical research and technology development organization that was founded in Seattle in 2009. We develop and apply open practices to data-intensive research for the advancement of human health. Data-intensive research has become an important component of biomedicine, but it`s not always easy to understand how to apply computational approaches appropriately or how to interpret their results. Sage believes open practices can help. Our interdisciplinary team of scientists and engineers work together to provide researchers access to technology tools and scientific approaches to share data, benchmark methods, and explore collective insights, all backed by Sage`s gold-standard governance protocols and commitment to user-centered design. Sage is supported through a portfolio of competitive research grants, commercial partnerships, and philanthropic contributions. Sage embraces diversity, equity and inclusion. We are committed to pay parity and making our salary ranges available to all employees. We invite you to apply and we welcome a conversation. We are based in Seattle, WA, and collaborate broadly throughout the world.
Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.